Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
2.340
-0.010 (-0.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst
August 10, 2022
Via
Benzinga
Revance Therapeutics: Q2 Earnings Insights
August 09, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Revance Therapeutics Q1 Earnings
May 10, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Revance Therapeutics Update
February 06, 2022
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options
Via
NewMediaWire
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For August 9, 2022
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Revance Therapeutics: Earnings Outlook
August 08, 2022
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.
Via
Benzinga
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
July 27, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Therapeutics's Return On Capital Employed Insights
June 13, 2022
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter.
Via
Benzinga
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 23, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
May 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
May 03, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For May 10, 2022
May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Via
Benzinga
NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc.
April 27, 2022
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by...
Via
SBWire
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
April 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines
April 21, 2022
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for...
Via
Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
April 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
March 28, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 21, 2022
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.
Via
Benzinga
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
March 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Therapeutics: Q4 Earnings Insights
February 28, 2022
Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Deadline Today Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 07, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.